Ballicules.com

Pirfenidone

ESBRIET

What it isTGF-beta-modulating antifibrotic; idiopathic pulmonary fibrosis.

Why this oneUnlike nintedanib, its tolerability profile centers on photosensitivity and appetite or weight loss rather than diarrhea.

What limits itGI upset, weight loss and photosensitivity limit use; monitor liver tests. CYP1A2 interactions matter, and smoking lowers exposure.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Idiopathic pulmonary fibrosisAdult267 mg TID801 mg TID (2,403 mg/day)2,403 mg/day

Titration Days 1-7: 267 mg TID; days 8-14: 534 mg TID; day 15 onward: 801 mg TID

Renal Use with caution in mild/moderate/severe impairment; not recommended in ESRD on dialysis

Hepatic Use with caution in mild/moderate (Child-Pugh A/B); not recommended in severe (Child-Pugh C)

Instructions

Cautions

Adverse reactions

Pregnancy Insufficient human data; not teratogenic in animals.

Lactation No information on presence in human milk.

NO BOXED WARNINGS

Principal riskPhotosensitivity and weight loss

Cost, est. cash$100–$5,000/month

Generic entry2022

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilitySerious infection, cytopenias, hepatic injury and malignancy risk require laboratory and clinical monitoring.

Mechanism of action: Pirfenidone ballicule

Pirfenidone ballicule: receptor binding, kinetics and half-life diagram

Open Pirfenidone in the interactive console ↗

Memory aids: mascots and interaction avatars

Pirfenidone ESBRIET mascot mnemonic cartoon
“Perfed’n’done Is brittle”
Pirfenidone CYP1A2 substrate avatar
CYP1A2 substrate

Open Pirfenidone in the interactive console ↗